U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07888933) titled 'Intravenous Ketamine for Acute Suicidal Crisis and Psychiatric Hospital Length of Stay' on Oct. 07.
Brief Summary: This randomized, double-blind, active placebo-controlled superiority trial will evaluate whether intravenous esketamine reduces time to psychiatric hospital discharge in adults hospitalized because of acute suicide risk. A total of 106 participants will be randomized in a 1:1 ratio to receive intravenous esketamine or midazolam as an active placebo. Participants assigned to esketamine will receive eight 40-minute intravenous infusions at a dose of 0.5 mg/kg administered twice weekly. The primary outcome is time from the...